Skip to main content
Suzhou Ribo Life Science Co., Ltd. logo

Suzhou Ribo Life Science Co., Ltd. — Investor Relations & Filings

Ticker · 6938 ISIN · CNE100007DS6 HKEX Manufacturing
Open in API
Filings indexed 41 across all filing types
Latest filing 2026-05-12 Governance Information
Country HK Hong Kong
Listing HKEX 6938

About Suzhou Ribo Life Science Co., Ltd.

https://www.ribolia.com

Suzhou Ribo Life Science Co., Ltd. is a clinical-stage biopharmaceutical company recognized as a global pioneer in the development of oligonucleotide-based therapeutics. The company is dedicated to advancing RNA interference (RNAi) technology, specifically focusing on siRNA therapeutics, to address significant unmet medical needs. Ribo Life has established a proprietary, fully integrated R&D platform that supports the entire lifecycle of oligonucleotide drug development, utilizing key innovations such as specialized siRNA delivery technology and RSC chemical modification technology. The company maintains an extensive siRNA drug pipeline, targeting core therapeutic areas including cardiovascular, metabolic, renal, and liver diseases, with a strong emphasis on chronic disease treatment.

Recent filings

Filing Released Lang Actions
H Share Option Scheme
Governance Information Classification · 80% confidence The document is the full text of the company’s H-Share Option Plan rules (“H股购股权计划”), detailing definitions, eligibility, terms of grant, exercise conditions and governance of the share option scheme. It is not a simple announcement of a report (RPA) nor a financing update, earnings release or management change notice. It is a corporate governance instrument setting out internal rules for equity incentives, thus fitting the Governance Information category (CGR).
2026-05-12 Chinese
H Share Incentive Scheme
Governance Information Classification · 75% confidence The document is the full terms and rules of the company’s H-share Equity Incentive Plan (definitions, grant conditions, vesting schedules, trustee arrangements, etc.). It is not announcing a specific transaction, not a simple notice or Q&A transcript, and it contains no financial statements. Rather, it sets out the internal governance policy and rules for equity awards – a corporate governance document. Therefore, it best fits the Governance Information category.
2026-05-12 Chinese
Form of Proxy for use at the 2025 Annual General Meeting to be held on Friday, June 5, 2026
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a Form of Proxy for the company’s 2025 Annual General Meeting, providing shareholders with a proxy appointment and voting instructions. This is a classic proxy solicitation document sent to shareholders to request votes for resolutions. Therefore, it fits the “Proxy Solicitation & Information Statement” category.
2026-05-12 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of the Company’s Annual General Meeting, setting out resolutions to be considered and soliciting proxies and votes from shareholders. It provides background information, voting procedures, and proxy details, fitting the definition of materials sent to shareholders to provide information and request votes for meetings. Therefore, it should be classified as a Proxy Solicitation & Information Statement (PSI).
2026-05-12 English
CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a shareholder circular containing detailed proposals (profit distribution plan, remuneration of directors, re-appointment of auditor, governance amendments, share scheme adoptions, mandates for issue/repurchase of shares, etc.) and the notice of the Annual General Meeting along with a proxy form. It is clearly sent to shareholders to provide information and solicit votes for the AGM. This matches the definition of a Proxy Solicitation & Information Statement.
2026-05-12 English
CHANGE OF DATE OF ANNUAL GENERAL MEETING AND BOOK CLOSURE PERIOD
Regulatory Filings Classification · 95% confidence The document is a formal announcement published on the Hong Kong Exchange relating to a corporate event (the rescheduling of the Annual General Meeting and the book closure period). It does not contain AGM presentation materials, voting results, financial statements, or proxy materials. It is a general regulatory announcement regarding corporate action, which falls under the catch-all Regulatory Filings category. Therefore, the correct classification is RNS.
2026-05-12 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.